Kosh Agarwal - Dissemin

Papers authored by Kosh Agarwal

This paper was not found in any repository, but could be made available legally by the author.

2017 Edward J. Gane, Stephen Pianko, Stuart K. Roberts, Alexander J. Thompson, Stefan Zeuzem, Eli Zuckerman, Ziv Ben-Ari, Graham R. Foster, Kosh Agarwal

, Alex L. Laursen, Jan Gerstoft, Wei Gao, Hsueh-Cheng Huang, Brian Fitzgerald, Doreen Fernsler and 16 other authors

Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials

Upload

Bo Wang

, Laura Abbott, Kate Childs, Chris Taylor, Kosh Agarwal

, Ian Cormack, Rosa Miquel, Abid Suddle

Dolutegravir-induced liver injury leading to sub-acute liver failure requiring transplantation: a case report and review of literature

Upload

This paper is made freely available by the publisher.

S. D. Shafran, D. Shaw, M. Charafeddine, K. Agarwal

, G. R. Foster, M. Abunimeh, T. Pilot-Matias, R. K. Pothacamury, B. Fu, E. Cohen, D. E. Cohen, E. Gane

Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II-III)

Download from doi.org

Gayatri Chakrabarty, Matthew Bruce, Mary Horner, Bo Wang, Kosh Agarwal

, Ivana Carey

Can quantitative hepatitis B surface antigen levels predict the severity of liver disease in genotype E Patients?

Download from onlinelibrary.wiley.com

J. R. Potts, C. M. Maybury

, A. Salam, J. N. Barker, K. Agarwal

, C. H. Smith

Diagnosing liver fibrosis: a narrative review of current literature for dermatologists

Upload

This paper is available in a repository.

Tania M. Welzel, Neeru Bhardwaj, Charlotte Hedskog, Krishna Chodavarapu, Gregory Camus, John McNally, Diana Brainard, Michael D. Miller, Hongmei Mo, Evguenia Svarovskaia, Ira Jacobson, Stefan Zeuzem, Kosh Agarwal

Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses

Download from kclpure.kcl.ac.uk

Paul Y. Kwo, Fred Poordad, Armen Asatryan, Stanley Wang, David L. Wyles, Tarek Hassanein, Franco Felizarta, Mark S. Sulkowski, Edward Gane, Benedict Maliakkal, J. Scott Overcash, Stuart C. Gordon, Andrew J. Muir, Humberto Aguilar, Kosh Agarwal

and 7 other authors

Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis

Upload

Ira M. Jacobson, Eric Lawitz, Edward J. Gane, Bernard E. Willems, Peter J. Ruane, Ronald G. Nahass, Sergio M. Borgia, Stephen D. Shafran, Kimberly A. Workowski, Brian Pearlman, Robert H. Hyland, Luisa M. Stamm, Evguenia Svarovskaia, Hadas Dvory-Sobol, Yanni Zhu and 15 other authors

Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials

Upload

Norah A. Terrault, Marina Berenguer, Simone I. Strasser, Adrian Gadano, Les Lilly, Didier Samuel, Paul Y. Kwo, Kosh Agarwal

, Michael P. Curry, Stefano Fagiuoli, James Y. Y. Fung, Edward Gane, Kimberly A. Brown, Patrizia Burra, Michael Charlton and 2 other authors

International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Recipients:

Upload

Norah A. Terrault, Geoff W. McCaughan, Michael P. Curry, Edward Gane, Stefano Fagiuoli, James Y. Y. Fung, Kosh Agarwal

, Les Lilly, Simone I. Strasser, Kimberly A. Brown, Adrian Gadano, Paul Y. Kwo, Patrizia Burra, Didier Samuel, Michael Charlton and 2 other authors

International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates:

Upload

Zobair M. Younossi, Maria Stepanova, Harry L. Janssen, Naoky Tsai, Kosh Agarwal

, Mindie H. Nguyen, Magdy Elkhashab, Issah Younossi, Sharon Hunt

Hepatitis B (HBV) Viral Suppression is Independently Associated with Better Patient-Reported Outcomes (PROS)

Upload

Kosh Agarwal

, Scott Fung, Wai-Kay Seto, Young-Suk Lim, Edward Gane, Harry L. Janssen, Wan-Long Chuang, Ho Bae, Ki Tae Yoon, John F. Flaherty, Audrey Lau, Anuj Gaggar, Vithika Suri, Andrea Cathcart, Lanjia Lin and 6 other authors

Week 96 Efficacy and Safety Results of Tenofovir Alafenamide (TAF) Comparing to Tenofovir Disoproxil Fumarate (TDF) in Chronic Hepatitis B (CHB), HBEAG-Positive Patients: A Global Phase 3 Study

Upload

Matteo A. Manini

, Matthew Bruce, Matteo Passerini, Tiong Y. Lim, Gavin Whitehouse, Ivana Carey, B. Wang, E. Gonsalkorala, Aisling Considine, Abid Suddle, Pietro Lampertico, Nigel Heaton, Michael Heneghan, Kosh Agarwal

Entecavir or tenofovir monotherapy prevents HBV recurrence in liver transplant recipients: A 5-year follow-up study after hepatitis B immunoglobulin withdrawal

Upload

Charlotte Warren-Gash, Alicia Thornton, Kate Childs, Sanjay Bhagani, Ankur Srivastava, Shirin Demma, Clifford Leen, Kosh Agarwal

, Aj Rodger, Ca Sabin

, Joint Uk Chic and liver transplant advisory Group

Cirrhosis and liver transplantation in patients co-infected with HIV and hepatitis B or C: an observational cohort study.

Download from researchonline.lshtm.ac.uk

H. L. Chan, S. Fung, W. K. Seto, E. Gane, J. F. Flaherty, V. Suri, L. Lin, A. Gaggar, G. M. Subramanian, W. L. Chuang, K. Agarwal

, H. L. Janssen, M. Buti

Improved bone and renal safety of switching from tenofovir disoproxil fumarate to tenofovir alafenamide: preliminary results from 2 phase 3 studies in HBeAg-positive and HBeAg-negative patients with chronic hepatitis B

Upload

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Marc Bourliere, Edward J. Gane, Ira Jacobson, Stuart C. Gordon, Mark S. Sulkowski, Brian L. McNabb, Frances Chen, Hadas Dvory-Sobol, John McNally, Diana M. Brainard, Mani Subramanian, Alnoor Ramji, Stefan Zeuzem, Kosh Agarwal

, K. Rajender Reddy

Long-Term Follow Up of Patients with Chronic HCV and No or Minimal Fibrosis Shows Low Risk for Liver-Related Morbidity and Mortality After Achieving SVR with DAA-Based Therapy: Results from the Gilead SVR Registry

Upload

Kosh Agarwal

, Sang Hoon Ahn, Magdy Elkhashab, Kyungpil Kim, Audrey H. Lau, Anuj Gaggar, Mani Subramanian, John G. McHutchison, Pietro Andreone, Hyung J. Kim, Wan-Long Chuang, Mindie H. Nguyen

Safety and Efficacy of Vesatolimod (GS-9620) in Patients with Chronic Hepatitis B (CHB) Who Are Not Currently on Antiviral Treatment

Upload

A. Thompson, A. Thompson, E. Gane, E. Gane, S. Fung, S. Fung, W. K. Seto, W. K. Seto, J. F. Flaherty, J. F. Flaherty, Suri, Suri, L. Lin, L. Lin, A. Gaggar and 13 other authors

Improved bone and renal safety of switching from tenofovir disoproxil fumarate to tenofovir alafenamide: Preliminary results from two phase 3 studies in HBeAg-positive and HBeAg-negative patients with chronic hepatitis B

Upload

Ivana Carey, Enoka Gonsalkorala, Matthew Bruce, Sarah Montague, Bo Wang, Ruth Byrne, Geoffrey M. Dusheiko, Kosh Agarwal

HBsAg and HBcrAg concentrations differ between genotype A1 and A2 HBeAg negative patients with chronic hepatitis B: complexity within sub-genotypes has implications for newer therapy paradigms

Upload

Ivana Carey, Matthew Bruce, Sarah Montague, Michelle Spaan, Ruth Byrne, Kate Childs, Bo Wang, Geoffrey M. Dusheiko, Kosh Agarwal

Hepatitis B core-related antigen (HBcrAg) is useful marker in HBV/HDV co-infection and can help to predict response to pegylated interferon therapy

Upload

Missing publications? Search for publications with a matching author name.

Researcher

Statistics

Refine

Papers authored by Kosh Agarwal